Abstract: Objective To better understand HBV infection status and the immunity effects of hepatitis B in the National Immunization Program in real-world clinical practice.Methods Data were retrieved from the SuValue database (including 63 tertiary and secondary hospitals across China) from January 2006 to July 2017. The positive rates of surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), and hepatitis B core anti-body (anti-HBc) were analyzed and compared with the results of the national seroepidemiological survey of hepatitis B in 2006 and 2014. Results A total of 2 311 221 participants were included in this study, including 919 908 men and 1 391 313 women. From 2006 to 2007, the overall positive rates of HBsAg, HBeAg and anti-HBc declined from 17.4%, 7.1%, 32.9% to 5.9%, 2.3%, 24.2%, whereas the positive rate of anti-HBs increased from 47.6% to 56.4%. Interestingly, the HBsAg positive rate in the groups of 1-4 years and 5-14 years in 2006 (1.4% and 9.1%) and 2014 (0.4% and 0.9%) were close to that in the national seroepidemiological survey of hepatitis B conducted in 2006 (0.96% and 10.6%) and 2014 ( 0.3% and 0.9%, P<0.05).Conclusion The big data from real-world clinical practice can be used to monitor the HBsAg positive rate and evaluate the immunity effect of hepatitis B vaccine in the National Immunization Program those younger than 15 years old.

Key words: HBV, Big medical data, Real world